SS-31 (Elamipretide) Deep Dive

SS-31, also designated elamipretide in the clinical literature, is a synthetic tetrapeptide that occupies a distinct position in mitochondrial research for one structural reason: it localizes to the inner mitochondrial membrane without requiring an intact electrochemical gradient to do so. That property distinguishes it from the majority of mitochondria-targeted research compounds, which rely on the membrane potential established by the electron transport chain to concentrate at their intended site. For preclinical researchers studying mitochondrial dysfunction in contexts where membrane potential itself is the variable under investigation — ischemia, aging, cardiomyopathy, neurodegeneration — this targeting independence is analytically meaningful.

Published research through mid-2026 now spans at least six distinct domains: cardiac function, cardiac senescence, neurological injury recovery, skeletal muscle bioenergetics, radiation-induced cardiomyopathy, and spinal cord injury. Across those domains, a consistent mechanistic frame recurs: SS-31 is examined as a tool for stabilizing cardiolipin — the phospholipid concentrated at the inner mitochondrial membrane that serves as the structural scaffold for electron transport chain complexes and for cristae architecture. The compound is classified as a research-use-only (RUO) material and is not approved or intended for administration to living subjects.

This document synthesizes the mechanistic basis of SS-31 research, surveys published findings across the six primary research domains active as of mid-2026, and provides compound handling and sourcing context for researchers and institutions.

Cardiolipin Affinity and Membrane Targeting

The mechanistic framework for SS-31 research begins with cardiolipin. Cardiolipin is a dimeric phospholipid comprising two phosphatidyl groups linked by a glycerol backbone — a structure that concentrates almost exclusively at the inner mitochondrial membrane. Cristae architecture, the folded inner membrane topology that creates the physical scaffolding for the electron transport chain, is stabilized by cardiolipin-protein interactions. Disruption of cardiolipin by oxidative modification — peroxidation of its four acyl chains — has been associated in preclinical literature with electron transport chain complex destabilization, impaired proton gradient maintenance, cristae remodeling, and initiation of mitochondrial apoptotic signaling.

SS-31 is a cationic, amphipathic tetrapeptide (sequence: D-Arg-Dmt-Lys-Phe-NH₂, where Dmt denotes 2′,6′-dimethyltyrosine) designed by Hazel Szeto and Peter Schiller to penetrate cell membranes and associate with the inner mitochondrial membrane through electrostatic and hydrophobic interactions with cardiolipin. Critically, this localization occurs independent of the transmembrane potential. In experimental contexts where membrane potential is collapsed — common in ischemia, senescence, and energy-depleted models — SS-31 can still be studied at its intended site of action, a property that makes it a useful probe for those exact pathological states.

The cardiolipin interaction has been characterized in published research as having two functional consequences under study: (1) reducing access of cytochrome c to cardiolipin, which is proposed to limit peroxidase-like oxidation of cardiolipin by the cytochrome c/cardiolipin complex; and (2) limiting peroxidation of cardiolipin’s polyunsaturated acyl chains by reactive oxygen species [doi:10.3892/ijmm.2024.5436]. Both effects converge on preserving the integrity of the cardiolipin–electron transport chain interaction.

Electron Transport Chain and ATP Production

Downstream of cardiolipin stabilization, the electron transport chain is the primary functional endpoint examined in SS-31 preclinical literature. Complexes I, III, IV, and V of the electron transport chain require cardiolipin for full catalytic function; destabilization of cardiolipin is associated with reduced electron flux, impaired proton pumping, decreased membrane potential, and reduced ATP synthase activity. In skeletal muscle aging models, SS-31 administration has been studied in relation to the ATP production rate directly: aged mouse skeletal muscle showed restored maximum mitochondrial ATP output after SS-31 treatment, at the level seen in young controls, without a corresponding change in mitochondrial volume or biogenesis [PMID: 42290373].

This finding is mechanistically distinct from compounds studied to promote mitochondrial biogenesis (PGC-1α agonists, NAD+ precursors, MOTS-c). SS-31 is not being examined as a trigger for generating more mitochondria — it is being examined as an agent that restores the function of existing mitochondrial membrane architecture when that architecture has been oxidatively compromised.

Reactive Oxygen Species, Ferroptosis, and Senescence Pathways

Recent preclinical literature has expanded the mechanistic picture beyond the cardiolipin–ETC–ATP axis in two directions.

Ferroptosis: A 2024 study in the International Journal of Molecular Medicine examined SS-31 in a diabetic cardiomyopathy model using H9C2 cardiac cells under high-glucose conditions and a diabetic mouse model. The study characterized a pathway connecting cardiolipin peroxidation to mitochondria-dependent ferroptosis — iron-dependent cell death mediated by lipid peroxidation — via mitochondrial glutathione peroxidase 4 (mitoGPX4). The proposed mechanistic sequence: SS-31 reduces cardiolipin oxidative damage → mitoGPX4 activity is preserved → ferroptotic lipid peroxidation cascade is attenuated [doi:10.3892/ijmm.2024.5436]. This positions SS-31’s cardiolipin interaction upstream of a cell-death pathway increasingly studied in metabolic and cardiac disease contexts.

Cellular Senescence: Two 2026 publications extended the mechanistic scope to cellular senescence — a state of permanent cell-cycle arrest associated with the senescence-associated secretory phenotype (SASP) and tissue dysfunction. In a radiation-induced cardiomyocyte senescence model, SS-31 was examined for effects on mitochondrial integrity and senescence markers in irradiated cardiac tissue [PMID: 42456009]. A parallel study using a doxorubicin-induced cardiac cell senescence model similarly examined SS-31 in relation to mitochondria-associated senescence pathways [PMID: 42450582]. Both studies operate from the hypothesis that mitochondrial dysfunction — including cardiolipin-related oxidative damage — is a driver, rather than merely a consequence, of the senescent phenotype, and that SS-31 may be a tool for interrogating that relationship in cardiomyocyte models.

α-Synuclein and Neurodegeneration: Published research in Chemistry & Biology & Drug Design (2026) investigated SS-31 in relation to α-synuclein modulation [PMID: 42219795]. α-Synuclein accumulation and aggregation at mitochondrial membranes has been proposed as a contributor to mitochondrial dysfunction in dopaminergic neuron degeneration models. The study examined whether SS-31’s membrane association properties interact with α-synuclein-mediated mitochondrial pathology — extending the compound’s research profile into neurodegeneration-adjacent territory without establishing clinical relevance.

1. Cardiac Protection and Cardiomyopathy

Cardiac research is the longest-established and most active domain in the SS-31 literature. The reasoning follows directly from cardiolipin biology: the heart is highly dependent on mitochondrial ATP production (cardiomyocytes derive approximately 90% of their ATP from oxidative phosphorylation), making cardiac tissue particularly sensitive to inner mitochondrial membrane disruption. Three overlapping subfields are active as of mid-2026.

Diabetic Cardiomyopathy (DCM): The 2024 IJMM study [doi:10.3892/ijmm.2024.5436] reported that SS-31 administration in a diabetic mouse model was associated with preserved fractional shortening and ejection fraction, as measured by echocardiography, alongside reduced serum lactate dehydrogenase and creatine kinase isoenzymes — markers of cardiomyocyte membrane integrity. The authors framed the findings in terms of the mitoGPX4-ferroptosis pathway described above.

Radiation-Induced Cardiomyopathy: Radiotherapy targeting thoracic malignancies can result in cardiac complications months to years after treatment. The 2026 Journal of Radiation Research study [PMID: 42456009] examined SS-31 in a radiation-induced cardiomyocyte senescence model, investigating whether mitochondria-targeted antioxidant intervention could attenuate the mitochondrial dysfunction component of radiation-associated cardiac injury. This is a recognized research gap: standard cardioprotection strategies are limited, and mechanistic characterization of mitochondria-targeted approaches is an active area.

Chemotherapy-Associated Cardiotoxicity: Doxorubicin, an anthracycline chemotherapeutic, produces dose-dependent cardiac toxicity associated with mitochondrial ROS generation and cardiomyocyte senescence. The 2026 Biology (Basel) study [PMID: 42450582] examined SS-31 in a doxorubicin-induced cardiac senescence model, characterizing the compound as a mechanistic probe for the mitochondrial contribution to anthracycline-related cardiotoxicity.

2. Skeletal Muscle Bioenergetics and HFpEF

Published in Circulation: Heart Failure in 2026, the HFpEF skeletal muscle study [PMID: 42290373] examined SS-31’s effects on skeletal muscle mitochondrial function in a heart failure model. HFpEF is associated with exercise intolerance driven partly by peripheral — rather than solely central cardiac — impairment, with skeletal muscle bioenergetics emerging as a key research variable. The study examined whether SS-31 could restore ATP production capacity in the skeletal muscle of HFpEF model animals, and reported improvements in muscle mitochondrial ATP production and exercise performance metrics. This represents a more granular research question than general “mitochondrial function”: the study isolates skeletal muscle bioenergetics as the target system and frames SS-31 as a probe for whether cardiolipin-targeted intervention can address the peripheral muscle component of HFpEF-associated exercise limitation.

3. Neurological Injury Recovery

Mitochondrial dysfunction is an established early event in ischemia-reperfusion brain injury, preceding cell death and influencing the extent of neurological damage. Two 2026 publications investigated SS-31 in neurological injury contexts.

Post-Ischemic Brain Injury (SS-31 + NMN Combination): A 2026 Neurochemical Research study [PMID: 42443448] examined the combination of SS-31 and nicotinamide mononucleotide (NMN) in a post-ischemic brain injury model. The study characterized the combination’s effects on TREM2 expression — a microglial receptor associated with neuroinflammatory regulation — and downstream neuroinflammatory signaling. The mechanistic hypothesis: SS-31 addresses inner mitochondrial membrane integrity while NMN supports NAD+-dependent mitochondrial function; the combination may access parallel mitochondrial recovery pathways.

Spinal Cord Injury Recovery: Published in Neurochemistry International [PMID: 42082001], this 2026 study examined SS-31 in a spinal cord injury (SCI) model, reporting effects on mitochondrial bioenergetics preservation and neural remodeling — including axonal and synaptic plasticity markers — following SCI. SS-31’s targeting mechanism is particularly relevant to the secondary injury phase, when membrane potential is compromised and potential-dependent compounds have reduced uptake. The neural remodeling findings extend the research question from acute mitochondrial protection into longer-term structural recovery, though the study is preclinical.

4. Ophthalmology and Age-Related Macular Degeneration

The retinal pigment epithelium (RPE) is among the most metabolically active cell populations in the body. RPE cells support photoreceptor function through sustained phagocytosis of shed outer segments — tasks that place continuous demand on mitochondrial ATP production. Age-related RPE dysfunction underlies the pathology of geographic atrophy and age-related macular degeneration (AMD). A 2021 review in Cells [PMID: 34572131] surveyed therapeutic candidates for AMD and included SS-31/elamipretide among the compounds examined for cytoprotective mechanisms in RPE aging models, characterizing it in the context of mitochondrial dysfunction and ROS accumulation. This review situates SS-31 within the AMD research landscape as an investigational candidate, not an established intervention.

5. α-Synuclein and Parkinson’s-Adjacent Neurodegeneration

The 2026 Chemistry & Biology & Drug Design study [PMID: 42219795] investigated SS-31 in relation to α-synuclein — the protein whose misfolding and aggregation is implicated in Parkinson’s disease pathology. α-Synuclein can associate with mitochondrial membranes, and its accumulation has been proposed to impair Complex I function and increase ROS production at the inner mitochondrial membrane. The study examined SS-31’s interaction with this pathway, exploring whether the compound’s cardiolipin affinity is relevant to α-synuclein-associated mitochondrial dysfunction. The findings represent a mechanistic hypothesis rather than a clinical conclusion; research in this domain remains at the preclinical characterization stage.

SS-31 belongs to the Szeto-Schiller peptide family, a class of synthetic tetrapeptides with a recurring structural motif: alternating aromatic and basic residues. This pattern generates an amphipathic, cationic molecule capable of intercalating into lipid bilayers and interacting with anionic phospholipid headgroups through both electrostatic attraction and hydrophobic insertion.

Sequence: D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2′,6′-dimethyltyrosine; D-Arg = D-arginine enantiomer; C-terminus is an amide). The use of a D-amino acid at the N-terminus confers partial resistance to aminopeptidases. The Phe-NH₂ C-terminus reduces carboxypeptidase susceptibility.

Molecular weight: ~639 g/mol (free base form). Typically supplied as an acetate or trifluoroacetate salt for solubility.

Solubility: High aqueous solubility driven by the guanidinium group (D-Arg) and the ε-amino group (Lys). SS-31 is typically reconstituted in sterile water or isotonic aqueous buffer for research applications.

Storage: Lyophilized SS-31 should be stored at −20°C or below under dry conditions. Aqueous solutions are subject to oxidative degradation; researchers typically prepare small working aliquots and minimize freeze-thaw cycling.

Membrane targeting: Unlike triphenylphosphonium-conjugated compounds (MitoQ, SkQ1) that require a negative mitochondrial membrane potential to accumulate via electrophoretic uptake, SS-31 targets the inner mitochondrial membrane through direct physicochemical affinity for cardiolipin. This membrane-potential-independent mechanism is the compound’s defining characteristic from a research tool standpoint.

Research on SS-31 is preclinical in the domains reviewed above, with the exception of its appearance in a Phase 3 clinical trial program (MMPOWER-3, primary mitochondrial myopathy; ReDUCE, Barth syndrome). MMPOWER-3 missed its primary endpoint (6-minute walk test improvement in the overall cohort). A pre-specified subgroup analysis found a statistically significant improvement in patients with nuclear DNA–encoded mitochondrial myopathy gene variants; that finding is the basis for the NuPOWER follow-up trial.

These clinical trial outcomes do not alter the compound’s RUO status and are not directly relevant to its use as a preclinical mechanistic probe. They are relevant context for researchers situating preclinical findings within the broader landscape of mitochondria-targeted peptide research.

Additionally, a preclinical study examined SS-31 in a spinal cord injury and disuse model and reported no detectable effect on muscle mass or gene expression versus placebo in that specific context. The pattern across multiple preclinical studies suggests SS-31’s effects are most consistently observed in models where mitochondrial energy production — specifically cardiolipin-dependent electron transport — is the direct bottleneck. Models where muscle wasting is driven primarily by neural or inflammatory mechanisms rather than direct mitochondrial failure have shown less consistent findings.

Researchers should evaluate SS-31 against the mechanistic hypothesis most relevant to their model system, not as a universal mitochondrial protectant.

SS-31 (elamipretide) for preclinical and in vitro research is available from peptide suppliers providing certificates of analysis documenting compound identity, HPLC purity, and mass spectrometry confirmation. Given SS-31’s susceptibility to oxidative degradation in solution, supplier documentation of cold-chain handling and lyophilized storage conditions is a relevant procurement consideration. Researchers conducting cell-based assays, ischemia-reperfusion models, cardiomyopathy models, or neurological injury studies should confirm purity of ≥98% by HPLC and identity by high-resolution mass spectrometry before use in publication-grade experiments.

Stackhaus Research (stackhausresearch.com) supplies research-grade SS-31 with supporting COA documentation for qualified researchers and institutions operating under research-use frameworks. All material is supplied under a research-use-only designation; not for diagnostic, therapeutic, or veterinary use.

What is SS-31?

SS-31, also known as elamipretide, is a synthetic cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH₂, developed in the laboratory of Hazel Szeto (Szeto-Schiller peptide 31). It is studied in preclinical research for its localization to the inner mitochondrial membrane, where it interacts with cardiolipin — the phospholipid central to electron transport chain organization and cristae architecture. SS-31 is a research-use-only compound and is not approved or intended for therapeutic or diagnostic application.

How does SS-31 differ from MitoQ or other mitochondria-targeted antioxidants?

The primary distinguishing feature is targeting mechanism. MitoQ, SkQ1, and related triphenylphosphonium-conjugated compounds accumulate in the mitochondrial matrix via electrophoresis driven by the negative mitochondrial membrane potential. In cell or tissue models where membrane potential is severely compromised — as occurs in ischemia, advanced heart failure, or heavily oxidized mitochondria — this uptake mechanism is impaired. SS-31 reaches the inner mitochondrial membrane through direct physicochemical affinity for cardiolipin and does not require an intact membrane potential for localization. This makes it a distinct research probe for studying mitochondrial dysfunction in contexts where membrane potential itself is the variable under investigation.

What research domains is SS-31 currently studied in?

As of mid-2026, published preclinical research on SS-31 spans cardiac protection (diabetic cardiomyopathy, radiation-induced cardiomyopathy, chemotherapy cardiotoxicity), skeletal muscle bioenergetics in heart failure with preserved ejection fraction (HFpEF), neurological injury recovery (post-ischemic brain injury, spinal cord injury), age-related macular degeneration (RPE cytoprotection models), and α-synuclein-associated mitochondrial dysfunction.

What are the key published PMIDs for SS-31 research through 2026?

Selected verified publications:

• PMID 42290373 — Skeletal muscle ATP production in HFpEF model (Circulation: Heart Failure, 2026)
• PMID 42456009 — Radiation-induced cardiomyocyte senescence (J Radiat Res, 2026)
• PMID 42450582 — Doxorubicin-induced cardiac cell senescence (Biology (Basel), 2026)
• PMID 42443448 — SS-31 + NMN combination, TREM2, post-ischemic brain injury (Neurochem Res, 2026)
• PMID 42219795 — α-Synuclein modulation (Chem Biol Drug Des, 2026)
• PMID 42082001 — Spinal cord injury mitochondrial bioenergetics and neural remodeling (Neurochem Int, 2026)
• PMID 34572131 — AMD/retinal pigment epithelium review (Cells, 2021)
• doi:10.3892/ijmm.2024.5436 — Diabetic cardiomyopathy, mitoGPX4-ferroptosis pathway (IJMM, 2024)

Is SS-31 available for research?

SS-31 is available as a research-use-only compound from specialized peptide suppliers with appropriate COA documentation. Stackhaus Research supplies SS-31 for qualified research use. All material is intended solely for in vitro and preclinical laboratory investigation; not for administration to human or animal subjects, diagnosis, or therapeutic use.

Research Use Only. SS-31 (elamipretide) is supplied for laboratory research purposes only. Not intended for administration to subjects, diagnostic use, or therapeutic application. All information is for educational and research purposes only. Consult primary literature for experimental applications.